Form 4: Cognition Therapeutics CEO's Stock Activity
Insider Transaction Report
Cognition Therapeutics CEO Lisa Ricciardi acquired 75,000 shares through PSU vesting and disposed of 23,400 shares for tax obligations.
Summary
- Lisa Ricciardi, CEO and President of Cognition Therapeutics Inc. (CGTX), reported transactions involving the company's common stock.
- On December 18, 2025, Ricciardi acquired 75,000 shares of common stock at a price of $0.00 per share.
- These shares were earned upon the vesting of performance stock units (PSUs) granted on February 14, 2024, with the remaining 50% vesting on December 18, 2025.
- Also on December 18, 2025, Ricciardi disposed of 23,400 shares of common stock at a price of $1.50 per share.
- This disposition represents shares withheld by the Issuer to cover tax withholding obligations related to the PSU vesting.
- Following these transactions, Ricciardi directly beneficially owns 990,266 shares of common stock.
- Additionally, Ricciardi indirectly beneficially owns 38,851 shares of common stock through her spouse.
- The transactions were made pursuant to a Rule 10b5-1 plan.
Sentiment
Score: 6
Explanation: The sentiment is moderately positive. The vesting of performance stock units indicates the achievement of company goals, which is a positive sign. The subsequent sale for tax purposes is a standard practice and does not reflect negatively on the company's performance or outlook.
Positives
- The vesting of 75,000 performance stock units indicates the achievement of certain performance goals by the company, which is a positive signal for operational execution.
Negatives
- The disposition of 23,400 shares to cover tax withholding obligations, while a common practice, represents a reduction in direct beneficial ownership.
Future Outlook
This filing does not contain forward-looking statements or guidance regarding the company's future financial performance or strategic outlook.
Industry Context
This Form 4 filing details a routine insider transaction related to executive compensation, specifically the vesting of performance-based equity awards and subsequent tax withholding. Such transactions are common across all industries for publicly traded companies and do not inherently reflect broader industry trends or competitive positioning.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Transaction Plan Disclosure | The reported transactions were made pursuant to a Rule 10b5-1(c) contract, instruction, or written plan for the purchase or sale of equity securities. | 12/18/2025 | The use of a Rule 10b5-1 plan demonstrates a commitment to transparent and pre-arranged insider trading, mitigating concerns about opportunistic trading based on material non-public information. |
Related Party Transactions
- Indirect beneficial ownership of 38,851 shares of common stock is held by the reporting person's spouse.
Stakeholder Impact
- Shareholders: Provides transparency into executive stock ownership and compensation, confirming the vesting of performance-based awards.
- Management: Reflects the realization of performance-based compensation for the CEO.
Key Dates
| Date | Description |
|---|---|
| 02/14/2024 | Date performance stock units (PSUs) were granted to the reporting person. |
| 12/18/2025 | Date of the reported transactions (acquisition of shares from PSU vesting and disposition for tax withholding). |
| 12/22/2025 | Date the Form 4 was signed by the reporting person. |
Keywords
Cognition Therapeutics, CGTX, Insider Transaction, Form 4, Lisa Ricciardi, CEO, Performance Stock Units, PSU Vesting, Stock Ownership, Rule 10b5-1
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.